SOUTH SAN FRANCISCO, Calif.,
Oct. 13, 2016 /PRNewswire/
-- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics
company that reduces unnecessary surgeries and healthcare costs by
resolving diagnostic uncertainty, announced that external
researchers will present data from three studies reinforcing the
clinical impact and value of the company's Percepta®
Bronchial Genomic Classifier and Envisia™ Genomic Classifier – for use in lung cancer and
idiopathic pulmonary fibrosis (IPF) diagnosis, respectively – at
the CHEST Annual Meeting 2016, being held October 22-26 in Los
Angeles.
During the meeting, external researchers will also share data
evaluating the ability of the Envisia classifier to enable improved
diagnosis of IPF.
"The findings being presented at this year's CHEST meeting
highlight our continued focus on both developing advanced genomic
classifiers that have a tangible, positive impact on patient care
and securing the clinical evidence that gives physicians and
insurers the confidence they need to adopt these valuable
diagnostic tests," said Bonnie
Anderson, Veracyte's president and chief executive
officer.
Following is a summary of the abstracts that will be presented
at CHEST 2016*:
Title:
|
Impact of a Bronchial
Genomic Classifier for Lung Cancer on Reducing Invasive Procedure
Recommendations Across Variations in Pulmonology Practices (Session
4030)
|
Presenter:
|
Ryan Van Wert, M.D.
(Stanford University)
|
Date/Time:
|
Sunday, October 23,
5:15-5:30 p.m.
|
|
Title:
|
Understanding the
Patient Journey of Interstitial Lung Disease Diagnosis: The
INTENSITY Survey (Session 4150)
|
Presenter:
|
Gregory P. Cosgrove,
M.D. (National Jewish Health)
|
Date/Time:
|
Wednesday, October
26, 8:45-9:00 a.m.
|
|
Title:
|
The PERCEPTA
Registry: A Prospective Registry to Evaluate Percepta Bronchial
Genomic Classifier Patient Data (Board #908)
|
Presenter:
|
D. Kyle Hogarth, M.D.
(University of Chicago)
|
Date/Time:
|
Wednesday, October
26, 1:30-2:30 p.m.
|
|
* All times are
Pacific Daylight Time (PDT)
|
In addition, during a private event scheduled for Monday, October 24, Fernando J. Martinez, M.D. (Weill Cornell
Medical College) will present data supporting the advancement of
Veracyte's Envisia classifier.
About Veracyte
Veracyte (NASDAQ: VCYT)
is pioneering the field of molecular cytology, offering genomic
solutions that resolve diagnostic ambiguity and enable physicians
to make more informed treatment decisions at an early stage in
patient care. By improving preoperative diagnostic accuracy, the
company aims to help patients avoid unnecessary invasive procedures
while reducing healthcare costs. Veracyte's
Afirma® Thyroid FNA Analysis centers on the
proprietary Afirma Gene Expression Classifier (GEC) and is becoming
a new standard of care in thyroid nodule assessment. The Afirma
test is recommended in leading practice guidelines and is covered
for 185 million lives in the United
States, including through Medicare and many commercial
insurance plans. Veracyte is expanding its molecular
cytology franchise to other clinical areas, beginning with
difficult-to-diagnose lung diseases. In 2015, the company
launched the Percepta® Bronchial Genomic
Classifier, a test to evaluate patients with lung nodules that are
suspicious for cancer, which has already received draft Medicare
coverage. In the fourth quarter of 2016, Veracyte plans to
launch its second pulmonology product, the Envisia™ Genomic
Classifier, to improve diagnosis of interstitial lung diseases,
including idiopathic pulmonary fibrosis. For more information,
please visit www.veracyte.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "expect," "believe," "should," "may," "will" and
similar references to future periods. Examples of forward-looking
statements include, among others, statements we make regarding our
beliefs regarding the drivers of adoption of Afirma, our
expectations with respect to the success of our entry into the
pulmonology market, our expectations regarding full-year 2016
guidance and forecast for annual GEC test volume, and the value and
potential of our technology and research and development pipeline.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, anticipated
events and trends, the economy and other future conditions.
Forward-looking statements involve risks and uncertainties, which
could cause actual results to differ materially, and reported
results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not
limited to: our limited operating history and history of
losses; our ability to increase usage of and reimbursement for
Afirma and to obtain reimbursement for any future products we may
develop or sell; our ability to continue our momentum and growth;
our dependence on a few payers for a significant portion of our
revenue; the complexity, time and expense associated with billing
and collecting from payers for our tests; laws and regulations
applicable to our business, including potential regulation by
the Food and Drug Administration or other regulatory
bodies; our ability to develop and commercialize new products
and the timing of commercialization; the size of the market
opportunity for our products; our ability to successfully achieve
adoption of and adequate reimbursement for our products; the amount
by which use of our products are able to reduce invasive procedures
and reduce healthcare costs; our ability to achieve sales
penetration in complex commercial accounts; the occurrence and
outcome of clinical studies; the timing and publication of study
results; the applicability of clinical results to actual outcomes;
our inclusion in clinical practice guidelines; the continued
application of clinical guidelines to our products; our ability to
compete; our ability to obtain capital when needed; and other risks
set forth in the company's filings with the Securities and
Exchange Commission, including the risks set forth in the company's
Quarterly Report on Form 10-Q for the quarter ended June 30,
2016. These forward-looking statements speak only as of the date
hereof and Veracyte specifically disclaims any obligation
to update these forward-looking statements.
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the
Afirma logo are trademarks of Veracyte, Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/data-demonstrating-clinical-value-of-veracyte-genomic-tests-for-use-in-lung-cancer-and-ipf-to-be-presented-at-chest-annual-meeting-2016-300344055.html
SOURCE Veracyte